Halozyme Therapeutics Shares Decline Following Wells Fargo Rating Change
Monday, 7 October 2024, 16:28
Halozyme Therapeutics Experiences Stock Decline
Halozyme Therapeutics (HALO) ticked lower on Monday, experiencing a stock price decline following a downgrade from Wells Fargo. The financial institution has adjusted its rating to equal weight, suggesting a cautious outlook for the company.
Details of the Downgrade
Wells Fargo set a price target of $62 per share for Halozyme, indicating limited upside potential that may worry investors. Analysts are taking a critical view of the biotechnology company amidst shifting market dynamics.
- Company: Halozyme Therapeutics
- New Rating: Equal Weight
- Price Target: $62 per share
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.